Dosis der Nierenersatztherapie bei akutem Nierenversagen

Summary

Acute kidney injury in the ICU is increasing dramatically worldwide, making the need for renal replacement therapy (RRT) greater than ever. Unresolved issues are questions like when do we start RRT and how do we measure its dose. Several recent trials could show that the relationship between dose of RRT and survival is not a linear one, leaving it to the discretion of the nephrologist and/or intensivist to choose the mean of RRT and its dose in a complex therapeutic concept for the critically ill patient. Highly efficient means of RRT eliminate potentially life-saving drugs like antibiotics to a larger extent than one or two decades ago. As sepsis is responsible for the onset of acute renal failure in more than half of the patients careful adjustment (i. e. increase) of the dose of antibiotics is crucial to avoid under-dosing of these drugs. This holds also true for the nutritional support of these patients as increasing the dose of renal replacement therapy also enhances the elimination of nutrients.

akutes Nierenversagen - Nierenersatztherapie - Dialysedosis

acute kidney injury - renal replacement injury - dialysis frequency

Literatur

• 1 Bouman C S, Van Oudemans-Straaten H M, Tijssen J G, Zandstra D F, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial.  Crit Care Med. 2002;  30 2205-2211
• 2 Burkhardt O, Hafer C, Langhoff A, Kaever V, Kumar V, Welte T, Haller H, Fliser D, Kielstein J T. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis.  Nephrol Dial Transplant. 2009;  24 267-271
• 3 Centre for Disease Control . Hospitalization Discharge Diagnoses for Kidney Disease – United States, 1980 – 2005.  MMWR. 2008;  57 309-312
• 4 Czock D, Husig-Linde C, Langhoff A, Schopke T, Hafer C GK, Swoboda S, Kuse E, Haller H, Fliser D, Keller F, Kielstein J T. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.  Clin J Am Soc Nephrol. 2006;  1 1263-1268
• 5 Davenport A, Bouman C, Kirpalani A, Skippen P, Tolwani A, Mehta R L, Palevsky P M. Delivery of renal replacement therapy in acute kidney injury: what are the key issues?.  Clin J Am Soc Nephrol. 2008;  3 869-875
• 6 Eloot S, Van Biesen W, Dhondt A, WH, Glorieux G, Verdonck P, Vanholder R. Impact of hemodialysis duration on the removal of uremic retention solutes.  Kidney Int. 2008;  73 765-770
• 7 Faulhaber-Walter R, Hafer C, Jahr N, Vahlbruch J, Hoy L, Haller H, Fliser D, Kielstein J T. The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit.  Nephrol Dial Transplant. 2009;  24 2179-2186
• 8 Kielstein J T, Czock D, Schopke T, Hafer C, Bode-Boger S M, Kuse E, Keller F, Fliser D. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis.  Crit Care Med. 2006;  34 51-56
• 9 Kielstein J T, Kretschmer U, Ernst T, Hafer C, Bahr M J, Haller H, Fliser D. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study.  Am J Kidney Dis. 2004;  43 342-349
• 10 Mueller B A, Pasko D A, Sowinski K M. Higher renal replacement therapy dose delivery influences on drug therapy.  Artif Organs. 2003;  27 808-814
• 11 Palevsky P M, Zhang J H, O’Connor T Z, Chertow G M, Crowley S T, Choudhury D, Finkel K, Kellum J A, Paganini E, Schein R M, Smith M W, Swanson K M, Thompson B T, Vijayan A, Watnick S, Star R A, Peduzzi P. Intensity of renal support in critically ill patients with acute kidney injury.  N Engl J Med. 2008;  359 7-20
• 12 Ratanarat R, Brendolan A, Piccinni P, Dan M, Salvatori G, Ricci Z, Ronco C. Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival.  Crit Care. 2005;  9 R294-R302
• 13 Roberts J A, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient.  Crit Care Med. 2009;  37 840-851
• 14 Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La G G. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial.  Lancet. 2000;  356 26-30
• 15 Saudan P, Niederberger M, SS, Romand J, Pugin J, Perneger T, Martin P Y. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure.  Kidney Int. 2006;  70 1312-1317
• 16 Schiffl H, Lang S M, Fischer R. Daily hemodialysis and the outcome of acute renal failure.  N Engl J Med. 2002;  346 305-310
• 17 Tolwani A J, Campbell R C, Stofan B S, Lai K R, Oster R A, Wille K M. Standard versus high-dose CVVHDF for ICU-related acute renal failure.  J Am Soc Nephrol. 2008;  19 1233-1238
• 18 Uchino S, Kellum J A, Bellomo R, Doig G S, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C. Acute renal failure in critically ill patients: a multinational, multicenter study.  JAMA. 2005;  294 813-818
• 19 Vesconi S, Cruz D N, Fumagalli R, Kindgen-Milles D, Monti G, Marinho A, Mariano F, Formica M, Marchesi M, Rene R, Livigni S, Ronco C. Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury.  Crit Care. 2009;  13 R57